ItaCORMs: conjugation with a CO-releasing unit greatly enhances the anti-inflammatory activity of itaconates†

Abstract

Endogenous itaconate as well as the gasotransmitter CO have recently been described as powerful anti-inflammatory and immunomodulating agents. However, each of the two agents comes along with a major drawback: Whereas itaconates only exert beneficial effects at high concentrations above 100 μM, the uncontrolled application of CO has strong toxic effects. To solve these problems, we designed hybrid prodrugs, i.e. itaconates that are conjugated with an esterase-triggered CO-releasing acyloxycyclohexadiene–Fe(CO) ₃ unit ( ItaCORMs). Here, we describe the synthesis of different ItaCORMs and demonstrate their anti-inflammatory potency in cellular assays of primary murine immune cells in the low μmolar range (<10 μM). Thus, ItaCORMs represent a promising new class of hybrid compounds with high clinical potential as anti-inflammatory agents.

Abstract

New powerful anti-inflammatory agents (prodrugs) were developed which act by esterase-triggered, simultaneous release of itaconate and the gasotransmitter carbon monoxide.